An Open-label Extension Study to Evaluate the Safety and Tolerability of Sotatercept (MK-7962) Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518687-12-00

Acronym

MK-7962-031

Enrollment

Registered

2025-05-26

Start date

2025-06-19

Completion date

Unknown

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension (PAH)

Brief summary

Number of participants with one or more adverse events (AEs), Number of participants who discontinue study intervention due to an AE

Interventions

DRUGsotatercept

DRUGSOTATERCEPT

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants with one or more adverse events (AEs), Number of participants who discontinue study intervention due to an AE	—

Countries

Czechia, France, Hungary, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026